FDA-cleared profile

EFAI RTSuite CT HN-Segmentation System

Ever Fortune.AI Co., Ltd.

EFAI RTSuite CT HN-Segmentation System automatically delineates head-and-neck organs at risk on adult non-contrast CT images to support radiation-treatment workflows; initial contours are transferred to a DICOM-compliant treatment-planning system for professional review and editing.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
EFAI RTSuite CT HN-Segmentation System automatically delineates head-and-neck organs at risk on adult non-contrast CT images to support radiation-treatment workflows; initial contours are transferred to a DICOM-compliant treatment-planning system for professional review and editing.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Radiation-oncology departments using compatible planning, imaging, and treatment-delivery systems.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
Radiotherapy contouring, treatment planning, adaptation, or treatment-session support under professional review.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Supported CT or MR images, structures, prescriptions, plans, registrations, and treatment-session data.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Contours, treatment plans, adapted plans, dose or evaluation results, or session information requiring review and approval.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220264
FDA source Exact FDA submission Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Head and neck organs at risk
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2022-04-28
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The exact FDA package describes DICOM CT input and DICOM or RTSTRUCT organ-at-risk output to a DICOM-compliant treatment-planning system; verify exact local compatibility.
FDA source Exact FDA submission Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.

Deployment and data flow
The exact FDA package describes a specialized server on a local network for the EFAI HN-Segmentation release; verify current topology, service responsibility, and site configuration locally.
FDA source Exact FDA submission Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-04
Monitoring and change control
Monitor K220264 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.
FDA source Exact FDA submission Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K220264 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact FDA package describes a specialized server on a local network for the EFAI HN-Segmentation release; verify current topology, service responsibility, and site configuration locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact FDA package describes DICOM CT input and DICOM or RTSTRUCT organ-at-risk output to a DICOM-compliant treatment-planning system; verify exact local compatibility.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K220264 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Initial head-and-neck organ-at-risk contours require professional review and editing; the labeled system is not a decision-making or lesion-detection system.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. radiotherapy planning or image-processing software limits remain submission-specific.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K220264 FDA decision material describes the cleared radiotherapy planning or image-processing software, labeled use, and submission-specific verification. It does not establish product-wide sensitivity, specificity, outcomes, or independent clinical validation for this exact configuration.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K220264 FDA evidence package for EFAI RTSuite CT HN-Segmentation System

FDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission. · Head and neck organs at risk

exact submission · Tested version: EFAI RTSuite CT HN-Segmentation System configuration described in K220264 · Sponsor or vendor study

K220264

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
Public source Not applicable Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K220264 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
10Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact-name and exact-submission searches in the checked 2026-09-01 indexes returned no PubMed records and no ClinicalTrials.gov records for K220264; review status is candidate_review_pending. Literature and registry candidates remain quarantined unless exact submission and tested-version linkage is established. The checked recall disposition is no exact-submission recall record was promoted; ambiguous or family-only candidates are not published. Pricing, complete security architecture, contracted deployment, exact reimbursement, and local interoperability remain unverified. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K251351

AccuContour 4.0

Manteia Technologies Co., Ltd.

AccuContour 4.0 uses deep-learning contours to support segmentation of organs at risk on CT images for radiation-treatment planning, evaluation, and adaptation; qualified...

Modality
Radiotherapy Planning Imaging
Anatomy
Head and neck, thorax, abdomen, and pelvis organs at risk
Decision
2026-01-23
FDA-cleared K250035

Contour ProtégéAI+

MIM Software Inc.

Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive;...

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomical regions; prostate, seminal vesicles, and urethra on T2 MR
Decision
2025-02-03
FDA-cleared K231765

Contour ProtégéAI

MIM Software Inc.

Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive...

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Decision
2023-11-08